Occupier

Find Out The Latest

Keep in touch with news and developments from The Oxford Science Park and its occupiers here.

You can also follow us on LinkedIn

Scripta Therapeutics raises $12M to find disease-modifying drugs that alter transcription factor activity

13 Nov 2025

Scripta Therapeutics, based at The Oxford Science Park, has emerged from stealth by announcing a $12 million seed round to upend conventional approaches to drug discovery. Scripta combines AI, imaging, and patient-derived models to create and modulate disease maps based on transcriptional networks, building a new biology-first paradigm to decode and undo the programs that drive disease. The round is led jointly by Oxford Science... Read more

Theolytics appoints new Chief Medical Officer

08 Oct 2025

Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has announced the appointment of Matilde Saggese, MD, as Chief Medical Officer (CMO). Dr Saggese will lead clinical development and regulatory activities for Theolytics, including for its lead asset THEO-260, which is being investigated in UK and US trials evaluating two different routes of administration (IV and IP, respectively) in... Read more

Sitryx receives FDA clearance to progress trials of oral treatment of atopic dermatitis

03 Oct 2025

Sitryx Therapeutics, a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for SYX-5219, to support the initiation of a Phase 1b trial in adults with moderate to severe atopic dermatitis in the United States. The Company expects to... Read more

Tres Alchemix raises $4.4M in Series A funding to accelerate AI-driven drug discovery

26 Sep 2025

Tres Alchemix, an early-stage biotechnology company applying artificial intelligence (AI) to drug discovery, today announced it has closed a $4.4 million Series A financing. The round was led by DNX Ventures, with participation from existing investor Waseda University Ventures. The funding will accelerate development of Tres Alchemix’s predictive AI platform and support the opening of a new laboratory at The Oxford Science Park, a hub of... Read more

Moa and Nufarm announce next phase for their novel mode of action herbicide

22 Sep 2025

Moa Technology and Nufarm have announced the start of the next phase of their collaboration to bring an exciting novel mode of action agricultural herbicide to the global market, reaching this stage over a year earlier than typical industry timelines. The two companies have together assessed several promising novel mode of action compounds identified by Moa’s GALAXY discovery platform. These have demonstrated strong and consistent efficacy... Read more

News